A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

NCT00788593 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Pancreatitis
Exocrine Pancreatic Insufficiency

Interventions

DRUG: Placebo
DRUG: EUR-1008 (APT-1008) High Dose
DRUG: EUR-1008 (APT-1008) Low Dose

Sponsor

Forest Laboratories